Millions of people experience menstrual cramps, and the solutions are becoming more accessible. The global Dysmenorrhea Treatment Market is witnessing significant growth, with a projected Compound Annual Growth Rate (CAGR) of 8.3% from 2023 to 2033. This translates to an estimated market value of USD 6.3 billion in 2023, surging to a staggering USD 13.9 billion by 2033.
Dysmenorrhea, a prevalent condition affecting women globally, is characterized by painful menstruation. Prostaglandins, hormones generated in the uterine lining during menstruation, play a pivotal role in triggering uterine muscle spasms that cause pain and limit uterine blood flow and oxygen. Various underlying diseases can contribute to menstrual issues, emphasizing the need for effective dysmenorrhea treatment solutions.
Request a Sample PDF of this Report Now!
The team of analysts at Future Business Insights is focussing on research and market study to produce different Dysmenorrhea Treatment Market forecasts and predictions at both national and international levels. They have considered several leads of information on the industry like market figures and merger estimations to assess and produce reliable and informative insights on the Dysmenorrhea Treatment Market.
Dysmenorrhea Treatment Market Key Companies Profiled:
- Novartis Pharmaceuticals Corporation,
- Merck, Inc.,
- Bayer Schering Pharma AG,
- Vanita Therapeutics,
- Alvogen,
- Pfizer, Inc.,
- Nua
- Cora
- Roche Laboratories,
- Taj Pharmaceuticals, Ltd.,
- Sanofi,
- Terramedic, Inc.
To Get Insightful Details Buy This Report Now!
Key Segments Profiled In The Dysmenorrhea Treatment Market
By Diseases:
- Primary Dysmenorrhea
- Secondary Dysmenorrhea
- Endometriosis
- Adenomyosis
- Uterine Myomas
- Endometrial Polyps
- Cervical Stenosis
- Obstructive Malformations Of Genital Tract
By Therapeutic Class:
- Non-Hormonal Medical Treatment
- Non-steroidal anti-inflammatory Drugs (NSAIDS)
- Non-Selective NSAIDs
- Cox-2 Inhibitors
- Transdermal Glyceryl Trinitrate
- Over-The-Counter (Otc) Medications
- Hormonal Medicine Treatment
- Combined Oral Contraceptive
- Progestin Regimens
- Levonorgestrel Intrauterine System (LN-IUS)
- Surgical Options
- Laparoscopy
- Hysterectomy
- Presacral Neurectomy
- Laparoscopic Uterosacral Nerve Ablation (LUNA)
- Intrauterine Device (IUD)
By Region:
- North America
- Latin America
- Eastern Europe
- Western Europe
- APAC
- Japan
- MEA
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
